| News
BaseLaunch funds four healthcare ventures
05.02.2019
BaseLaunch supports carefully selected ventures in two phases. After an intense pressure test period, four projects were selected for Phase II of our second year. They now have the opportunity to further advance their breakthrough healthcare innovation and secure further investment.
BaseLaunch
The four healthcare ventures Anaveon, Pattern Biosciences, Synendos Therapeutics and a biotech in stealth mode receive funding of up to 250,000 Swiss francs as well as further support from BaseLaunch and its partners. Additionally, these projects have free-of-charge access to BaseLaunch’s co-working space and fully equipped shared laboratory in the Switzerland Innovation Park Basel Area in Allschwil.
This package allows the teams to focus on what truly matters: advancing and de-risking their science and further developing their ventures.
Applications for the BaseLaunch accelerator 2019 are now open
Further, BaseLaunch opens the next round of its accelerator program. The initiative, managed by BaselArea.swiss, is looking for people and projects with breakthrough healthcare innovations mainly in the field of therapeutics. However, applications are also open for game-changing innovation in diagnostics, medtech or related fields.
During Phase I, the selected projects develop their cases in Basel while having access to up to 10,000 Swiss francs each for consultancy and other services.
Phase II lasts at least twelve months, with each project receiving funding of up to 250,000 Swiss francs for further developing their venture.
Find out more about BaseLaunch and how to apply.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Yokogawa establishes innovation center in Allschwil
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.
Read More
Basel gains new biotech in Bright Peak
Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.
Read More
Robots from Basel set to revolutionize surgery
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.
Read More
T3 Pharma raises over 25 million Swiss francs
T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.
Read More
Versameb raises 6 million Swiss francs
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.
Read More
Genedata accelerating drug development
Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.
Read More
Basel is “probably the most productive life sciences location in the world”
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.
Read More
Basel Area cantons publish joint economic report
The cantons of Basel-Landschaft, Basel-Stadt and Jura have just published their first joint Economic Report. The fundamental environment is described as “good” in the report.
Read More
Resistell receives high-level EU grant
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.
Read More
Switzerland Innovation Park Basel Area Site Novartis Campus
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.
Read More
